Loading...
NPI 1437298189 · Stamford, CT · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Richard Weber is a ophthalmology physician provider located in Stamford, Connecticut. This profile covers 14 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Richard Weber |
| Address | 1275 Summer St |
| City | Stamford |
| State | CT |
| ZIP | 06905 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | February 6, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $884.1K |
| Medicaid | $0 |
This provider’s billing is effectively single‑payer: Total Medicare revenue is $884.1K while reported Medicaid revenue is $0, indicating Medicare is the exclusive payer of record in the dataset. The NPI was enumerated 2007-02-06 (~19 years ago), so this is a long‑tenured individual practitioner in Stamford, CT with an established Medicare billing history.
Revenue is highly concentrated in a very small set of services: the precomputed top 3 Medicare codes by revenue account for 80.8% of this provider’s total Medicare revenue. Those top three codes are J0178 (66.3% of Medicare revenue), 67028 (7.6%), and 99214 (6.9%), showing that a handful of items dominate the billing profile.
Clinical mix and service line implications point to a retina‑focused ophthalmology practice: J0178 (Injection, aflibercept) is the single largest revenue driver at $585.4K revenue from 846 claims, and 67028 (intravitreal injection) appears as the second major procedural code with $66.8K from 718 claims. High volume of 92134 (1.4K claims, $45.5K revenue) — computerized retinal imaging — further supports that the practice delivers frequent anti‑VEGF injections supported by retinal imaging diagnostics.
Although J0178 generates the majority of revenue, the provider’s national standing for that code is not dominant: J0178 ranks #1454 of 3204 providers nationally (55th percentile) and is labeled as "typical, unremarkable volume for this code." Similarly, 67028 ranks #1781 of 4255 (58th percentile) and is also characterized as typical, so the provider is a mid‑pack participant in anti‑VEGF/injection services rather than a national leader.
Visit and evaluation patterns show heavy established‑patient throughput with elevated coding activity: 99213 appears as an "extreme outlier, far above typical national volume for this code" (891 claims, $59.7K revenue, 6.8% of Medicare revenue), while 99214 (609 claims, $60.9K revenue, 6.9%) is high volume but labeled "typical, unremarkable volume." The presence of 99205 at a "notably above typical" level (125 claims, $21.4K revenue, 2.4%) also indicates meaningful high‑complexity new‑patient visits, suggesting both steady follow‑up and some inbound higher‑acuity referrals.
Diagnostic and procedural intensity is concentrated in retina imaging and extended ophthalmoscopy: 92134 is "notably above typical national volume" (1.4K claims, $45.5K revenue, 5.1%), and 92202 is also "notably above typical" (1.3K claims, $16K revenue, 1.8%). This pattern—high OCT/OCT‑interpretation volume alongside frequent injections—aligns with a workflow centered on monitoring and treating retinal disease.
Drug mix and payment profile indicate reliance on aflibercept over bevacizumab in Medicare billings: J0178 (aflibercept) accounts for $585.4K (66.3% of Medicare revenue) whereas J9035 (bevacizumab) accounts for $15.7K (1.8% of Medicare revenue) and ranks at a typical volume level (#506 of 1852, 73rd percentile). From a business perspective, the practice’s economics will be sensitive to utilization, pricing, or formulary shifts that affect aflibercept use.
Concentration risk and competitive positioning: with 80.8% of Medicare revenue coming from the top three codes and a single drug code (J0178) representing 66.3% of Medicare revenue, the practice has a concentrated revenue base that could amplify the financial impact of changes in drug selection, reimbursement, or care pathways. National rank descriptors across key codes (mix of "typical" for injections and "notably above typical" or "extreme outlier" for several E/M and imaging codes) depict an established, busy retina clinic that is neither a nationwide dominant injector nor a low‑volume provider, but rather a high-volume local operator with some nationally elevated activity in office visits and retinal diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
14 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 850 | $690 | $585.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 720 | $90 | $66.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 610 | $100 | $60.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 890 | $70 | $59.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,420 | $30 | $45.5K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 130 | $170 | $21.4K |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 1,340 | $10 | $16K |
| J9035 | Injection, bevacizumab, 10 mg | 280 | $60 | $15.7K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 210 | $20 | $4K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 30 | $120 | $3.8K |
Showing 1–10 of 14
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
14 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 21 | 40 | 830 | $690 | $713.1K |
| 67028 | 22 | 50 | 540 | $100 | $66.4K |
| 92235 | 21 | 30 | 40 | $110 | $14.8K |
| 99214 | 205 | 6,480 | 90 | $90 | $14.2K |
| J9035 | 8 | 30 | 130 | $50 | $10.4K |
| 99213 | 48 | 6,440 | 70 | $60 | $8.1K |
| 92134 | 16 | 320 | 60 | $30 | $7.7K |
| 99205 | 2 | 800 | 20 | $160 | $4.6K |
| 92250 | 223 | 430 | 60 | $30 | $3.1K |
| 92202 | 1 | 50 | 140 | $10 | $3K |
Showing 1–10 of 14
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 10 | $0 | $0 |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 20 | $0 | $0 |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 10 | $0 | $0 |
| 92226 | N/A | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Connecticut providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Connecticut median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 395 | 410 | 700 | $40 | $99.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 52 | 60 | 290 | $10 | $31.7K |
| 92226 | N/A | 22 | 20 | 260 | $10 | $9.6K |
| 92202 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 25 | 30 | 70 | $1 | $3.7K |
Other providers in the same ZIP code as Richard Weber, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.